source
- Sentynl inks up to $475M licensing deal to commercialize Mereo’s alvelestat for rare lung diseaseSentynl Therapeutics, a subsidiary of Zydus Lifesciences, signed an agreement to obtain exclusive U.S. rights to market alvelestat, Mereo BioPharma’s investigational therapy for alpha-1 antitrypsin…
- Eli Lilly sues six U.S. entities over illegal retatrutide sales, urges broader crackdownEli Lilly announced legal action against six U.S. entities accused of selling its experimental obesity drug retatrutide on the black market. The lawsuits target compounding pharmacies, medical spa…